- Home
- RNTX vs NTIP Comparison
RNTX vs NTIP Comparison
Compare RNTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- NTIP
- Stock Information
- Founded
- RNTX 2001
- NTIP 1990
- Country
- RNTX United States
- NTIP United States
- Employees
- RNTX N/A
- NTIP N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- RNTX Health Care
- NTIP Miscellaneous
- Exchange
- RNTX Nasdaq
- NTIP Nasdaq
- Market Cap
- RNTX 34.6M
- NTIP 32.0M
- IPO Year
- RNTX N/A
- NTIP 1998
- Fundamental
- Price
- RNTX $1.43
- NTIP $1.49
- Analyst Decision
- RNTX Buy
- NTIP
- Analyst Count
- RNTX 2
- NTIP 0
- Target Price
- RNTX $10.00
- NTIP N/A
- AVG Volume (30 Days)
- RNTX 114.1K
- NTIP 10.3K
- Earning Date
- RNTX 11-13-2025
- NTIP 10-24-2025
- Dividend Yield
- RNTX N/A
- NTIP 6.71%
- EPS Growth
- RNTX N/A
- NTIP N/A
- EPS
- RNTX N/A
- NTIP N/A
- Revenue
- RNTX N/A
- NTIP $150,000.00
- Revenue This Year
- RNTX N/A
- NTIP N/A
- Revenue Next Year
- RNTX N/A
- NTIP N/A
- P/E Ratio
- RNTX N/A
- NTIP N/A
- Revenue Growth
- RNTX N/A
- NTIP N/A
- 52 Week Low
- RNTX $1.04
- NTIP $1.16
- 52 Week High
- RNTX $4.40
- NTIP $1.90
- Technical
- Relative Strength Index (RSI)
- RNTX 60.90
- NTIP 44.71
- Support Level
- RNTX $1.22
- NTIP $1.48
- Resistance Level
- RNTX $1.30
- NTIP $1.53
- Average True Range (ATR)
- RNTX 0.11
- NTIP 0.04
- MACD
- RNTX 0.00
- NTIP -0.01
- Stochastic Oscillator
- RNTX 66.15
- NTIP 8.78
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.